| Combination of | |
|---|---|
| Memantine | NMDA receptor antagonist |
| Donepezil | Acetylcholinesterase inhibitor |
| Clinical data | |
| Trade names | Namzaric |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Memantine/donepezil, sold under the brand nameNamzaric among others, is afixed dose combination medication used for the treatment ofdementia of theAlzheimer's type.[1] It containsmemantine hydrochloride (it acts as anNMDA receptor antagonist, among various other types of targets like5-HT3 receptor,Nicotinic acetylcholine receptor, andSigma-1 receptor) anddonepezil hydrochloride, which is anacetylcholinesterase inhibitor.[1] It is takenby mouth.[1]
Memantine/donepezil was approved for medical use in the United States in 2014.[3]
 | Thispharmacology-related article is astub. You can help Wikipedia byadding missing information. |
